Treatment of Moderate to Severe Lateral Canthal Lines
Launched by GALDERMA R&D · Jan 29, 2020
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Male or female 18 years of age or older.
- • 2. Moderate to severe LCL at maximum smile as assessed by the Investigator.
- • 3. Moderate to severe LCL at maximum smile as assessed by the subject.
- Exclusion Criteria:
- • 1. Previous use of any Botulinum toxin treatment in facial areas within 9 months prior to study treatment.
- • 2. Female who is pregnant, breast feeding, or intends to conceive a child during the study.
- • 3. Known allergy or hypersensitivity to any component of the investigational product (QM1114-DP) or any botulinum toxin serotype.
About Galderma R&D
Galderma R&D is a global leader in dermatological innovation, dedicated to advancing skin health through rigorous research and development. With a strong commitment to scientific excellence, Galderma focuses on creating effective and safe treatments for a variety of skin conditions, including acne, rosacea, and psoriasis. The organization collaborates with healthcare professionals and researchers worldwide to bring cutting-edge solutions to market, ensuring that patients receive the highest quality care. Through its extensive clinical trials and commitment to regulatory compliance, Galderma R&D strives to enhance the understanding of dermatological diseases and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mount Kisco, New York, United States
Manhattan Beach, California, United States
Chapel Hill, North Carolina, United States
San Diego, California, United States
Solana Beach, California, United States
Boynton Beach, Florida, United States
Baltimore, Maryland, United States
Victor, New York, United States
Vancouver, British Columbia, Canada
Vancouver, British Columbia, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials